No Data
CSTONE PHARMA-B: 2024 ANNUAL REPORT
BeiGene (02616) will showcase five of its latest research achievements at AACR 2025.
The latest preclinical research results of five self-developed Innovative Drugs by Basestone Pharmaceuticals (02616) will be showcased at the annual meeting of the American Association for Cancer Research (AACR).
Hong Kong stocks have fluctuated | The Innovative Drugs Concept has seen significant gains. Institutions state that there is no need to pay tariffs on the licensing fees for Innovative Drugs, and support policies for Innovative Drugs are expected to be gr
The Innovative Drugs Concept has seen significant growth, as of the time of reporting, LAEKNA-B (02105) is up 13.16%, priced at 12.04 Hong Kong dollars; BRII-B (02137) is up 12.35%, priced at 1.82 Hong Kong dollars; CSTONE PHARMA-B (02616) is up 10.88%, priced at 2.65 Hong Kong dollars; BEIGENE (06160) is up 8.27%, priced at 148 Hong Kong dollars; HBM HOLDINGS-B (02142) is up 7.41%, priced at 7.68 Hong Kong dollars.
More Unpleasant Surprises Could Be In Store For CStone Pharmaceuticals' (HKG:2616) Shares After Tumbling 31%
CSTONE PHARMA-B (02616) completed the placement of 80 million shares, raising approximately 0.232 billion Hong Kong dollars.
CSTONE PHARMA-B (02616) announced that all conditions for the placement have been met, and the placement has been completed in April 2025...
CSTONE PHARMA-B (02616.HK) received a Shareholding increase of 0.56 million shares by CEO and Executive Director Yang Jian, with a total Shareholding increase of 10.359 million shares.
Gelonghui, April 9 - CSTONE PHARMA-B (02616.HK) announced that the Chief Executive Officer, President of R&D, and Executive Director Yang Jianxin informed that from April 2 to April 7, 2025, he purchased a total of 0.56 million shares in the open market using his own funds, with a purchase price per share ranging from HKD 2.26 to HKD 3.29. Since assuming the position of CEO in August 2022, Yang Jianxin has cumulatively purchased a total of 10.359 million shares, at a purchase price per share ranging from HKD 0.82 to HKD 4.60. After this share purchase, Yang Jianxin holds a total equivalent to the company's announced date.
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
